Retinal Renin-Angiotensin System Modulators: A Recent Implication for Therapy in Glaucomatous Patients
Wrood S. Al-khfajy1, Ahmed Hamed Jwaid2, Zakariya Al-Mashhadani1
1Mustansiriyah University, College of Pharmacy, Department of Pharmacology and Toxicology, Baghdad, Iraq
2University of Baghdad, College of Pharmacy, Department of Pharmacology and Toxicology, Baghdad, Iraq
Received: 30-Jun-2018 , Accepted: 05-Aug-2018
Keywords: Renin-angiotensin system, Intraocular pressure, Glaucoma, Ocular disease, Pharmacologically applications
Full Text HTML
How to Cite this Article
Al-khfajy WS, Jwaid AH, Mashhadani ZA. Retinal Renin-Angiotensin System Modulators: A Recent Implication for Therapy in Glaucomatous Patients. UKJPB. 2018; 6(4): 11-18.
Glaucoma is the ultimate commonly acquired optic neuropathy. It signifies a public health challenge since it causes an irreversible blindness. The single known treatment of the disease is decreasing of intraocular pressure (IOP), which has been revealed to lessen glaucoma progress in a diversity of large proportions of clinical trials. Herein in this literature, we briefly define the optical Renin Angiotensin system (RAS) signaling pathway and define the most essential components, physiological actions of major angiotensin peptides, and the Renin Angiotensin system blockers. And discuss the potential implications of their modulators as a new therapeutic target in glaucoma. The literature has shown that the individual RAS modulators including, Angiotensin converting enzymes 1(ACE1) inhibitors, Angiotensin converting enzymes 2 (ACE2) Activators, Angiotensin receptor-1 (AT-1) blocker, and renin inhibitors have a potentials role in modulation of aqueous humour homodynamic, by neuroprotection of the retinal ganglion cells (RGC) and acceleration of the aqueous humour outflow. In conclusion, RAS modulators have an imperious role in lowering IOP, these compounds will pave the approach for prospect innovation, improvement, and publicizing of novel drugs to treat glaucoma and therefore, aid save vision for millions of people suffering with this slow progressive optic neuropathy.